The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients
Ronald F. Parsons(Emory University), Howard M. Gebel(Rush University Medical Center), Annette M. Jackson(Johns Hopkins University), Arslan Zahid(Emory University Hospital), F. Eun‐Hyung Lee(Emory University), Shalini Bumb(University of Cincinnati), Robert A. Bray(Emory University), Thomas C. Pearson(Emory Healthcare), Hannah Decker(University of California, San Francisco), Malek Kamoun(Hospital of the University of Pennsylvania), Christian P. Larsen(Emory University Hospital), Harold C. Sullivan(Emory University), Mandy L. Ford(Emory Healthcare), Matthew H. Levine(Broad Institute), Dongfeng Chen(Guangzhou University of Chinese Medicine), I.R. Badell(Emory University)
Cited by 25
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation
|Transplantation|2012|777
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571